Ergomed to check drug safety for US Covid-19 trial
Ergomed
1,346.00p
08:02 13/11/23
Ergomed said it would provide drug safety services for a US trial to assess the benefits of a rheumatoid arthritis treatment for patients suffering from severe coronavirus infections.
FTSE AIM All-Share
745.29
16:54 18/04/24
Pharmaceuticals & Biotechnology
21,132.77
17:14 18/04/24
The pharmaceutical services company said its PrimeVigilance division would provide the services. The AIM-listed company bought Ashfield Pharmacovigilance in January to extend its reach into the US market.
Miroslav Reljanović, Ergomed, said: "Covid-19 represents a severe and pressing challenge for all involved in the development of new medicines and we are proud to be expanding our involvement in the field by bringing our expertise in drug safety and pharmacovigilance to this programme.
"The rapid initiation of clinical trials and establishment of appropriate safety monitoring will be critical to providing new treatments which may improve outcomes for patients."
Ergomed shares, up 3% in 2020 as wider markets have fallen, rose 3.9% to 405p at 11:36 BST.